January 30, 2025

Low-cost cancer prevention: AI-generated influencers reach at-risk groups on social media

Low-cost cancer prevention: AI-generated influencers reach at-risk groups on social media

Artificial Intelligence (AI) is transforming cancer prevention: A groundbreaking study conducted at the German Cancer Research Center (DKFZ) demonstrates that AI-generated social media influencers can effectively reach at-risk groups with preventive health messages—at a fraction of the cost of traditional campaigns.

Instagram picture featuring the AI-generated travel influencer Wanda (channel: WandaforAwareness) applying sunscreen
© Jana Winterstein/DKFZ

In this pilot study, researchers created a virtual influencer named “Wanda” who shared educational content on Instagram about five key modifiable cancer risk factors: smoking, unhealthy diet, excessive sun exposure, alcohol consumption, and HPV infection. With a total advertising budget of just €100, the campaign reached nearly 10,000 users.

Jana Winterstein, PhD student at DKFZ, explains: “Our findings highlight that AI-powered influencers offer a highly cost-effective way to deliver cancer prevention messages to a broad audience. What’s particularly exciting is that we were able to reach targeted age groups with minimal financial and time investment.”

The study compared two advertising approaches—one automated and one tailored to specific demographics. While both achieved similar reach, targeted ads were more effective in engaging younger adults, whereas the automated algorithm also reached older users.

Titus Brinker, who initiated the project, emphasizes the potential impact of this research: “Cancer prevention often fails due to limited budgets. Our study shows that AI opens up entirely new possibilities—especially for organizations with scarce resources.”

The researchers see great potential in AI-driven influencers for future public health campaigns. Further studies will explore how larger-scale initiatives can be implemented and how users’ trust in virtual influencers—so-called parasocial relationships—affects engagement.

Publication:

Winterstein et al., European Journal of Cancer, 2025, https://www.ejcancer.com/article/S0959-8049(25)00032-2/fulltext

Our latest News

discover more
New Publication from Sciomics GmbH: Fimepinostat Promotes Apoptosis and Decreases Cytokine Secretion in NF2-Related Human Schwannoma Cells

New Publication from Sciomics GmbH: Fimepinostat Promotes Apoptosis and Decreases Cytokine Secretion in NF2-Related Human Schwannoma Cells

Nagel, A.; Hass, E.W.; Hayes, H.; Huelbes, L.; Oliveira, S.; Hardin, H.M.; Marasigan, M.; Nisenbaum, E.; Misztal, C.; Telischi, F.F.; et al. Fimepinostat Promotes Apoptosis and Decreases Cytokine Secretion in NF2-Related Human Schwannoma Cells. Int. J. Mol. Sci. 2026, 27, 2636. https://doi.org/10.3390/ijms27062636 https://www.mdpi.com/1422-0067/27/6/2636 Simple Summary This study focuses on the action of fimepinostat, a dual histone deacetylase (HDAC)/phosphosphoinositide-3 kinase […]

Fraunhofer IPA wins the “euRobotics Technology Transfer Award” together with Trumpf and Lorch

Fraunhofer IPA wins the “euRobotics Technology Transfer Award” together with Trumpf and Lorch

Technology transfer that works: At the “European Robotics Forum” (ERF) in late March, the trio of applicants won the prestigious award. The award recognizes research that has found its way into industrial applications. The application focused on a “no-code” solution that allows companies to deploy cobots without specialized knowledge or significant welding effort, even for […]

Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria Paris and Tarrytown, NY, April 13, 2026. The European Commission has approved Dupixent (dupilumab) for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in children aged two to 11 years with inadequate response to histamine-1 […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp